EICHOR
● Completed
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
Condition: Relapsed Small Cell Lung Cancer · Sponsor: PharmaMar
About this study
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (210)
| Ironwood Cancer & Research Centers | Chandler, Arizona, United States | — |
| Genesis Cancer and Blood | Hot Springs, Arkansas, United States | — |
| Florida Cancer Specialists - South | Fort Myers, Florida, United States | — |
| Florida Cancer Specialists - North | St. Petersburg, Florida, United States | — |
| Florida Cancer Specialists - Panhandle | Tallahassee, Florida, United States | — |
| Florida Cancer Specialists - East | West Palm Beach, Florida, United States | — |
| Duly Health and Care | Joliet, Illinois, United States | — |
| Norton Cancer Institue, Downtown | Louisville, Kentucky, United States | — |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | — |
| Oncology Hematology West, PC (Grand Island) | Grand Island, Nebraska, United States | — |
| Oncology Hematology West, PC dba Nebraska Cancer Specialists | Omaha, Nebraska, United States | — |
| FirstHealth Outpatient Cancer Center | Pinehurst, North Carolina, United States | — |
+ 198 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05153239